Zealand Pharma A/S (ZELA)

Currency in DKK
321.20
-20.00(-5.86%)
Closed·
ZELA is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
321.20351.00
52 wk Range
233.50556.00
Key Statistics
Prev. Close
341.2
Open
343
Day's Range
321.2-351
52 wk Range
233.5-556
Volume
568.82K
Average Volume (3m)
450.2K
1-Year Change
-8.3333%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ZELA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
442.57
Upside
+37.79%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet

Zealand Pharma A/S News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

8 Buy
8 Hold
1 Sell
Ratings:
17 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 442.57
(+37.79% Upside)

Earnings

Latest Release
Aug 13, 2026
EPS / Forecast
55.34 / 0.94
Revenue / Forecast
4.49B / 824.88M
EPS Revisions
Last 90 days

ZELA Income Statement

Compare ZELA to Peers and Sector

Metrics to compare
ZELA
Peers
Sector
Relationship
P/E Ratio
8.1x16.3x−0.4x
PEG Ratio
−0.15−0.040.00
Price/Book
1.2x5.1x2.6x
Price / LTM Sales
4.8x4.0x3.1x
Upside (Analyst Target)
25.3%49.5%47.8%
Fair Value Upside
Unlock13.1%6.2%Unlock

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
23.23M33.07%7.65B
Other Institutional Investors
10.20M14.52%3.36B
Public Companies & Retail Investors
36.81M52.41%12.12B
Total
70.24M100.00%23.12B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Van Herk Investments B.V.10.17%7,143,3052,351,576
Avoro Capital Advisors LLC5.68%3,991,5421,314,016

People Also Watch

2,027.0
GMAB
+0.10%
966.5
NKT
+0.68%
819.2
PNDORA
-2.15%
428.3
COLOb
-0.49%
295.00
ISS
+1.37%

FAQ

What Is the Zealand Pharma (ZELA) Stock Price Today?

The Zealand Pharma stock price today is 321.20 DKK.

What Stock Exchange Does Zealand Pharma Trade On?

Zealand Pharma is listed and trades on the Copenhagen Stock Exchange.

What Is the Stock Symbol for Zealand Pharma?

The stock symbol for Zealand Pharma is "ZELA."

What Is the Zealand Pharma Market Cap?

As of today, Zealand Pharma market cap is 22.27B DKK.

What Is Zealand Pharma's Earnings Per Share (TTM)?

The Zealand Pharma EPS (TTM) is 89.42.

When Is the Next Zealand Pharma Earnings Date?

Zealand Pharma will release its next earnings report on Nov 12, 2026.

From a Technical Analysis Perspective, Is ZELA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Zealand Pharma Stock Split?

Zealand Pharma has split 0 times.

How Many Employees Does Zealand Pharma Have?

Zealand Pharma has 544 employees.

What is the current trading status of Zealand Pharma (ZELA)?

As of Aug 15, 2026, Zealand Pharma (ZELA) is trading at a price of 321.20 DKK, with a previous close of 341.20 DKK. The stock has fluctuated within a day range of 321.20 DKK to 351.00 DKK, while its 52-week range spans from 233.50 DKK to 556.00 DKK.

What Is Zealand Pharma (ZELA) Price Target According to Analysts?

The average 12-month price target for Zealand Pharma is 442.57 DKK, with a high estimate of 745 DKK and a low estimate of 300 DKK. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +37.79% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.